Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Rhythm Pharmaceuticals (RYTM) over the last 10 years, with Q3 2025 value amounting to $18.8 million.

  • Rhythm Pharmaceuticals' Share-based Compensation rose 7098.45% to $18.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.1 million, marking a year-over-year increase of 5372.49%. This contributed to the annual value of $39.7 million for FY2024, which is 2189.97% up from last year.
  • As of Q3 2025, Rhythm Pharmaceuticals' Share-based Compensation stood at $18.8 million, which was up 7098.45% from $15.9 million recorded in Q2 2025.
  • Rhythm Pharmaceuticals' Share-based Compensation's 5-year high stood at $18.8 million during Q3 2025, with a 5-year trough of $4.6 million in Q1 2022.
  • Its 5-year average for Share-based Compensation is $8.4 million, with a median of $7.8 million in 2024.
  • As far as peak fluctuations go, Rhythm Pharmaceuticals' Share-based Compensation tumbled by 1117.32% in 2022, and later soared by 7956.63% in 2023.
  • Over the past 5 years, Rhythm Pharmaceuticals' Share-based Compensation (Quarter) stood at $4.7 million in 2021, then rose by 13.07% to $5.3 million in 2022, then soared by 64.06% to $8.7 million in 2023, then increased by 21.7% to $10.6 million in 2024, then soared by 78.19% to $18.8 million in 2025.
  • Its Share-based Compensation was $18.8 million in Q3 2025, compared to $15.9 million in Q2 2025 and $12.9 million in Q1 2025.